Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 2011

View Archived Issues

Pfizer offers overview of second quarter 2011

Sanofi discovers new lysophospholipid S1P1 receptor agonists

Axin-2 as a key regulator of remyelination

MSX-1 missense substitution linked to familial hypodontia

New voltage-gated calcium channel blockers synthesized

Novel chalcone-linked imidazolone compounds disclosed by CSIR

Addex patents novel metabotropic glutamate mGlu4 receptor modulators

Theravance presents new norepinephrine/serotonin reuptake inhibitors

Palatin Technologies confirms commencement of phase I trial of AZD-2820

AAA obtains rights to anticancer antibody fragment from Dompe

CBio presents data from phase IIa XToll trial in rheumatoid arthritis

Repros Therapeutics reports data from Androxal study in men with type 2 diabetes

Victrelis obtains approval in Canada for chronic hepatitis C

Decitabine plus carboplatin shows promise in phase II ovarian cancer trial

MMRF and Onyx launch carfilzomib expanded access program

Trius Therapeutics reaches agreement with FDA for phase III torezolid trial

Chains of magnetasomes show antitumor effects in preclinical study

MolMed to develop production process for gene therapy for GSK

Alexza resubmits NDA to FDA for AZ-004

Axanum obtains positive agreement for E.U. approval

Genmab reports topline results for ofatumumab in aggressive lymphoma

FDA continues review of EUSA Pharma's BLA for Erwinaze in acute lymphoblastic leukemia

Amgen presents highlights of second quarter 2011

STATegics receives grant to advance product candidates for Friedreich's ataxia

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...